Poly Medicure FY26: 12.3% Revenue Growth, FY27 Outlook

Strategic pivot toward high-technology medical devices

Poly Medicure Ltd (BSE: 531768) said FY26 was a year of deliberate transition, with the company upgrading its business model toward high-technology, high-complexity and higher-growth segments. Management highlighted focus areas such as orthopedics, cardiology and oncology, alongside a continued emphasis on import substitution. The company said it invested in high-technology verticals and expanded clinical and R&D teams even as external conditions turned challenging, especially in international markets.

This pivot matters because it changes the mix of products and markets Poly Medicure targets, and it also raises near-term execution demands such as regulatory approvals, product validation, and supply chain stability. Management’s comments also indicate the company is positioning itself to build a global brand in high-end medical devices.

Product launches and internal R&D ramp-up

Poly Medicure said it launched 35 new products across the group in FY26, including 20 products developed in-house. The company’s new-product push is aligned with the stated strategy of moving into higher-technology categories and strengthening the portfolio beyond established segments.

Management linked the transition to investments in clinical capabilities and R&D. While the company did not provide product-level revenue contributions in the provided details, the scale of launches suggests a broad pipeline aimed at increasing relevance in specialized therapy areas over time.

Expansion via Medyneo acquisition in Brazil

The company expanded its global footprint through the acquisition of Medyneo in Brazil. Management said the acquisition helps the group enter the market faster because Medyneo already has regulatory licenses in place. This is relevant in medical devices where time-to-market is often shaped by local compliance and approvals.

Poly Medicure also said integration is underway for acquisitions including PendraCare, Citieffe and Medyneo, with the intent of strengthening its reach in regions such as Latin America and Europe.

FY26 revenue growth: domestic outpaces international

Poly Medicure reported 12.3% growth in full-year consolidated revenue for FY26. The company also said domestic business grew by 20%, while international business grew by 9% during the year. Management pointed to a difficult external environment, particularly affecting international revenue, which also contributed to a slower 4% growth in stand-alone revenue.

The company’s audited disclosures included two consolidated revenue figures in the provided details: consolidated FY26 revenue was stated as ₹1,875.3 crore, while another line item listed consolidated FY26 revenue of ₹1,99,534.14 lakh, which equals ₹1,995.34 crore. Stand-alone FY26 revenue was reported as ₹1,78,238.25 lakh, or ₹1,782.38 crore, and also separately stated as ₹1,662.5 crore in the same set of details.

Q4 FY26: higher revenue, weaker margins

In Q4 FY26, Poly Medicure’s consolidated revenue from operations rose 21.25% year-on-year to ₹534.51 crore. However, consolidated net profit dropped 29.17% to ₹65.04 crore. Profit before tax increased 30.63% year-on-year to ₹85.22 crore.

Operating EBITDA declined 8% to ₹112.1 crore in Q4 FY26 from ₹121.9 crore in Q4 FY25. EBITDA margin contracted by 667 basis points to 21% from 27.6% a year earlier.

Segment-wise, the company reported infusion therapy revenue up 1.9% year-on-year to ₹256.1 crore. Renal segment revenue rose 21.3% to ₹56.2 crore, and revenue from the “others” segment increased 55.2% to ₹222.1 crore.

Stock reaction and dividend

Following the results, Poly Medicure shares declined 3.78% to close at ₹1,538.35. The board recommended a dividend of ₹3.5 per equity share (face value ₹5) for FY25-26, subject to shareholder approval.

The company also said audited standalone and consolidated financials for Q4 and FY26 were approved with an unmodified audit opinion.

Costs, logistics disruptions, and competition pressures

Management flagged multiple operating headwinds. The company said logistics challenges in West Asia have affected execution of pending orders due to shipping disruptions. It also said raw material costs, especially those linked to crude oil, are rising and are pressuring gross margins.

In the renal segment, Poly Medicure said Chinese imports are creating competitive pressure, supported by zero import duties under ASEAN agreements. Managing Director Himanshu Baid said the company is working with the Indian government on these challenges.

The company also noted that acquisitions such as Citieffe and PendraCare are operating at lower EBITDA margins, which is weighing on consolidated profitability.

Cash position and funding capacity for strategy

Poly Medicure reported consolidated cash and cash equivalents of about ₹842.2 crore as of March 31, 2026. Management said these cash reserves are earmarked for strategic initiatives. A strong cash position can support R&D, product launches, and integration efforts, particularly during periods of margin pressure.

FY27 guidance: revenue range and margins

Management guided consolidated revenue of ₹2,300 crore to ₹2,400 crore for FY27, and stand-alone revenue of ₹1,900 crore to ₹1,950 crore. Stand-alone EBITDA margin guidance was 25% to 27%, while consolidated EBITDA margin guidance was 23% to 25%.

The company also guided domestic business growth of 20% and international business growth of 15% into FY27. For the renal segment specifically, management projected 20% growth for FY27, even as it acknowledged competitive pressure from imports.

Key financial and guidance table

Why the update matters for investors

The FY26 commentary shows Poly Medicure balancing two tracks: defending performance amid logistics and input-cost pressures, while funding a strategic transition toward higher-technology devices. The Q4 pattern of higher revenue but lower margins reinforces management’s warning of gross margin headwinds from raw materials and logistics disruptions.

At the same time, the company’s FY27 guidance provides a clear numeric framework on expected revenue and margin ranges. The sizeable cash balance of ₹842.2 crore provides flexibility to support product development, integration of acquired businesses, and market expansion, although the near-term profitability impact of lower-margin acquisitions remains a factor.

Conclusion

Poly Medicure closed FY26 with 12.3% consolidated revenue growth, a broad set of product launches, and an expanded overseas footprint through the Medyneo acquisition in Brazil. The company also flagged margin pressure from raw material inflation and logistics disruptions, alongside competitive intensity in renal care.

Next, investor attention is likely to stay on execution against the FY27 revenue and margin guidance, progress on integration of PendraCare, Citieffe and Medyneo, and how quickly price hikes and cost initiatives offset the stated gross margin headwinds.